Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+)… Read more
Niagen Bioscience, Inc. (NAGE) - Total Liabilities
Latest total liabilities as of September 2025: $27.46 Million USD
Based on the latest financial reports, Niagen Bioscience, Inc. (NAGE) has total liabilities worth $27.46 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Niagen Bioscience, Inc. - Total Liabilities Trend (2007–2024)
This chart illustrates how Niagen Bioscience, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Niagen Bioscience, Inc. Competitors by Total Liabilities
The table below lists competitors of Niagen Bioscience, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wuxi Double Elephant Micro Fibre Material Co Ltd
SHE:002395
|
China | CN¥888.01 Million |
|
Gan Yuan Foods Co Ltd
SHE:002991
|
China | CN¥479.98 Million |
|
Round One Corporation
MU:RDN
|
Germany | €197.96 Billion |
|
Shanghai Shuixing Home Textile Co Ltd Class A
SHG:603365
|
China | CN¥729.82 Million |
|
Rio2 Limited
OTCQX:RIOFF
|
USA | $148.26 Million |
|
Ferm. Casino Mun. Canne
PA:FCMC
|
France | €170.47 Million |
|
Aurionpro Solutions Limited
NSE:AURIONPRO
|
India | ₹4.56 Billion |
|
Australian Ethical Investment Ltd
AU:AEF
|
Australia | AU$29.28 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Niagen Bioscience, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Niagen Bioscience, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Niagen Bioscience, Inc. (2007–2024)
The table below shows the annual total liabilities of Niagen Bioscience, Inc. from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $22.18 Million | -16.31% |
| 2023-12-31 | $26.51 Million | +4.42% |
| 2022-12-31 | $25.39 Million | -2.79% |
| 2021-12-31 | $26.11 Million | +19.05% |
| 2020-12-31 | $21.93 Million | +10.77% |
| 2019-12-31 | $19.80 Million | +31.54% |
| 2018-12-31 | $15.05 Million | +69.34% |
| 2017-12-31 | $8.89 Million | -9.08% |
| 2016-12-31 | $9.78 Million | -27.44% |
| 2015-12-31 | $13.47 Million | +79.22% |
| 2014-12-31 | $7.52 Million | +126.36% |
| 2013-12-31 | $3.32 Million | -34.11% |
| 2012-12-31 | $5.04 Million | +35.93% |
| 2011-12-31 | $3.71 Million | +136.04% |
| 2010-12-31 | $1.57 Million | -37.59% |
| 2009-12-31 | $2.52 Million | +7.87% |
| 2008-12-31 | $2.33 Million | +583386.75% |
| 2007-12-31 | $400.00 | -- |